Organogenesis

OverviewSuggest Edit

Organogenesis Inc. is a leading regenerative medicine company with the unique skill set to take complex, living therapies from research and development, through manufacturing, to successful commercialization to reach patients today. As a pioneer in the field of regenerative medicine, Organogenesis received the first FDA approval of a living, allogeneic, cell-based product Apligraf®, approved for the treatment of venous leg ulcers.

TypePrivate
Founded1985
HQCanton, MA, US
Websiteorganogenesis.com
Employee Ratings4.2

Latest Updates

Employees (est.) (Sept 2021)922(+2%)
Job Openings67
Cybersecurity ratingBMore

Key People/Management at Organogenesis

Gary S. Gillheeney

Gary S. Gillheeney

President and Chief Executive Officer, Director
Brian Grow

Brian Grow

Chief Commercial Officer
Patrick Bilbo

Patrick Bilbo

Chief Operating Officer
Antonio S. Montecalvo

Antonio S. Montecalvo

Vice President, Health Policy and Contracting
Henry Hagopian

Henry Hagopian

Senior Vice President, Finance and Treasurer
Lori Freedman

Lori Freedman

Vice President and General Counsel
Show more

Organogenesis Office Locations

Organogenesis has offices in Canton, San Diego and Kanton Reinach
Canton, MA, US (HQ)
85 Dan Rd
Canton, MA, US
150 Dan Rd
San Diego, CA, US
10933 N Torrey Pines Rd, La Jolla
Kanton Reinach, CH
Christoph Merian-Ring 11
Show all (4)

Organogenesis Financials and Metrics

Summary Metrics

Founding Date

1985

Organogenesis total Funding

$75 m

Organogenesis latest funding size

$20 m

Time since last funding

4 years ago

Organogenesis investors

Organogenesis's latest funding round in May 2017 was reported to be $20 m. In total, Organogenesis has raised $75 m
Show all financial metrics

Organogenesis Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

Organogenesis Online and Social Media Presence

Embed Graph

Organogenesis News and Updates

Net Health Partners with Organogenesis for More Efficient Insurance Benefits Verification

PITTSBURGH, Aug. 23, 2021 /PRNewswire/ -- Net Health, a leading provider of cloud-based software for specialty medical providers, announced today that Organogenesis Holdings Inc. (Nasdaq: ORGO), has become the first company to utilize Net Health® Wound Care's latest CTP Connections Module...

Organogenesis Holdings Inc. Announces New $200 Million Credit Agreement with Silicon Valley Bank

CANTON, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today ann…

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2021 Financial Results on August 9, 2021

CANTON, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today ann…

Thinking about trading options or stock in Ford, Organogenesis, Beyond Meat, Dollar Tree, or Plug Power?

NEW YORK, May 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for F, ORGO, BYND, DLTR, and PLUG. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...

CORRECTING and REPLACING – Organogenesis Holdings Inc. Reports First Quarter 2021 Financial Results

CANTON, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Organogenesis Holdings Inc. (Nasdaq: ORGO), please note that in the third bullet of the First Quarter 2021 Financial Results Summary, the net revenue from the sale of non-PuraPly products w…

Organogenesis Appoints Jon Giacomin to Board of Directors

CANTON, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today anno…
Show more

Organogenesis Frequently Asked Questions

  • When was Organogenesis founded?

    Organogenesis was founded in 1985.

  • Who are Organogenesis key executives?

    Organogenesis's key executives are Gary S. Gillheeney, Brian Grow and Patrick Bilbo.

  • How many employees does Organogenesis have?

    Organogenesis has 922 employees.

  • Who are Organogenesis competitors?

    Competitors of Organogenesis include ACell, Biocodex and Nielsen Biosciences.

  • Where is Organogenesis headquarters?

    Organogenesis headquarters is located at 85 Dan Rd, Canton.

  • Where are Organogenesis offices?

    Organogenesis has offices in Canton, San Diego and Kanton Reinach.

  • How many offices does Organogenesis have?

    Organogenesis has 4 offices.